AstraZeneca has enlisted the help of Lilly in the development of its new Alzheimer's candidate AZD3293. The drug is an oral beta secretase cleaving enzyme (BACE) inhibitor, which the companies ...

AstraZenecas drug Imfinzi (NASDAQ: AZN) has received U.S. approval to treat adult patients with muscle-invasive bladder cancer, a significant advancement in cancer therapy. The approval allows ...